"The current way that DSMBs are constituted and report has resulted in a loss of faith." NEJM
"He was one of the most prolific investigators in the area of postoperative pain management. His fraud sets back our knowledge in the field tremendously.” Dr. Steve Shafer, the editor in chief of Anesthesia & Analgesia. Continue reading →
"The vote is an enormous blow to Avandia and GlaxoSmithKline. The vast majority of panel members voted either to withdraw the drug or to allow continued sales only if strict controls are added" Continue reading →
The dust-up involving Dr. Charles Nemeroff and Dr. Thomas Insell, director of NIMH shines a light on NIH leaders whose failure to enforce federal disclosure requirements is brushed off with excuses so untenable they have the ring of theater of the absurd. Continue reading →
"Dr. Nemeroff has become the poster child for what’s wrong with academic medicine in our country." Dr. Thomas Insell, Director of the NIMH, quietly helped him get a prized position at the University of Miami.
A stunning admission of failure by major drug manufacturers who market drugs for the treatment of Alzheimer’s. "We really believe drugs are failing because we honestly don’t understand the disease."
Continue reading →
"The resulting frenzy of psychiatric diagnoses has damaged the credibility of everyone in the field." Continue reading →
"Does this appointment signify that Harvard Medical School intends to even further strengthen its research ties to the pharmaceutical industry?" Continue reading →
Twenty-two years after the US marketing of Prozac, JAMA meta-analysis shows antidepressants to be worthless for most of the people for whom they are prescribed.
"Only 3 patients were in remission without adverse effects at long-term follow-up." Continue reading →